Drug Profile
ER 32897
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Antihypertensives
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 17 Nov 2006 Discontinued - Preclinical for Hypertension in Japan (PO)
- 25 Jan 2000 No-Development-Reported for Hypertension in Japan (PO)
- 20 Feb 1997 Preclinical development for Hypertension in Japan (PO)